The investigational Bruton's tyrosine kinase inhibitor fenebrutinib reduced annualized relapse rates versus teriflunomide ...
Hosted on MSN
Can creatine supplements reduce depression symptoms?
Wildlife park sees "glimmer of hope" as it begins euthanizing lions Chris Hemsworth, Alzheimer's and why Hollywood is suddenly obsessed with caregiving Marjorie Taylor Greene Knows Exactly What She’s ...
The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...
In the CRL, the Agency concluded that the NDA could not be accepted due to issues that are inherent to real-world evidence and external control studies. The Food and Drug Administration (FDA) has ...
William Blair analyst Myles Minter downgraded Biohaven (BHVN) to Market Perform from Outperform. The announcement of a CRL for troriluzole in spinocerebellar ataxia halts not only a near-term source ...
A WOMAN from Taunton who thought she was experiencing menopause symptoms was shocked to discover she had two brain tumours. Elizabeth Murphy, 60, a Crown Court clerk from Taunton, began struggling to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback